Sutro Biopharma (STRO) EBITDA Margin (2017 - 2026)
Sutro Biopharma (STRO) posted EBITDA Margin of 576.5% for Q4 2025, down 15.31% sequentially from 499.94% in Q3 2025, and down 13584.0% YoY from N/an in Q4 2024.
Powered by 
Analysis
Sutro Biopharma (STRO) EBITDA Margin (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported EBITDA Margin for 9 years, with the latest figure at 576.5% in Q4 2025.
- Quarterly EBITDA Margin fell 13584.0% year-over-year to 576.5% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 162.53% (up 22180.0% YoY) and the FY2025 annual result came in at 154.53%, up 22981.0% from the prior year.
- EBITDA Margin slipped to 576.5% in Q4 2025 per STRO's latest filing, from 499.94% in the prior quarter.
- Over five years, EBITDA Margin peaked at 37.95% in Q4 2023 and troughed at 797.17% in Q3 2024.
- A 5-year average of 331.22% and a median of 363.52% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin soared 60817 bps in 2023, then slumped 53710 bps in 2024.
- Over 5 years, EBITDA Margin stood at 328.85% in 2021, then slumped by 73 bps to 570.23% in 2022, then jumped by 107 bps to 37.95% in 2023, then tumbled by 1261 bps to 440.66% in 2024, then plunged by 31 bps to 576.5% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 576.5%, 499.94%, and 5.25% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.36% |
| 10 | Sutro Biopharma | 332.59 Mn | 168.25 Mn | - | -303.77% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -303.77% |
| Dec 31, 2025 | -576.50% |
| Sep 30, 2025 | -499.94% |
| Jun 30, 2025 | -5.25% |
| Mar 31, 2025 | -393.78% |
| Dec 31, 2024 | -440.66% |
| Sep 30, 2024 | -797.17% |
| Jun 30, 2024 | -189.39% |
| Mar 31, 2024 | -435.05% |
| Dec 31, 2023 | 37.95% |
| Sep 30, 2023 | -260.07% |
| Jun 30, 2023 | -443.52% |
| Mar 31, 2023 | -333.26% |
| Dec 31, 2022 | -570.23% |
| Sep 30, 2022 | -84.34% |
| Jun 30, 2022 | -68.97% |
| Mar 31, 2022 | -663.59% |
| Dec 31, 2021 | -328.85% |
| Sep 30, 2021 | -407.12% |
| Jun 30, 2021 | -34.96% |